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K aposi’s sarcoma (KS) is one of the most common malignan-cies in many countries of sub-Saharan Africa—where ap-
proximately 84% of global cases occur (1). An endemic form of 
KS was first identified in these countries in the 1960s, present-
ing in male adults but rarely in women and young children (2,3). 
Subsequently, an HIV-associated form of KS, known as epidemic 
or AIDS-KS, emerged in both adults and children in parallel with 
the HIV/AIDS epidemic (4). For example, in Zambia, KS accounted 
for approximately 25% of all pediatric malignancies by 1992, with 
a peak incidence between one and two years of age, making it the 
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Abstract
Background: The risk of Kaposi’s sarcoma–associated herpesvirus (KSHV) acquisition among children is increased by HIV infec-
tion. Antiretroviral therapy (ART) was recently made widely available to HIV-infected children in Zambia. However, the impact 
of early ART on KSHV transmission to HIV-infected children is unknown.
Methods: We enrolled and followed a cohort of 287 HIV-exposed, KSHV-negative children under 12 months of age from Lusaka, 
Zambia, to identify KSHV seroconversion events. Potential factors associated with KSHV infection—with an emphasis on HIV, 
ART, and immunological measures—were assessed through structured questionnaires and blood analyses. Incidence rate, Ka-
plan-Meier, and multivariable Cox regression models were used to assess differences in time to event (KSHV seroconversion) be-
tween groups. All statistical tests were two-sided.
Results: During follow-up, 151 (52.6%) children underwent KSHV seroconversion. Based on 3552 months of follow-up, we ob-
served similar KSHV incidence rates between HIV-infected and uninfected children. Among HIV-infected children, ARTnaive chil-
dren had statistically significantly increased risk of KSHV acquisition (adjusted hazard ratio [AHR] = 5.04, 95% confidence inter-
val [CI] = 2.36 to 10.80, P < .001). Time-updated CD4+ T-cell percentage was also statistically significantly associated with risk 
of KSHV acquisition (AHR = 0.82, 95% CI = 0.74 to 0.92, P < .001), such that each 5% increase of CD4+ T-cells represented an 
18% decrease in risk of acquiring KSHV.
Conclusions: Our data suggest that early ART and prevention of immune suppression reduce the risk of KSHV acquisition among 
HIV-infected children in an area where both viruses are highly endemic. This study highlights the importance of programs in Af-
rica to provide children with ART immediately after HIV infection is diagnosed. 
1
digitalcommons.unl.edui it l .
2 L . N .  O l p  e t  a l  i n  J C N I  J o u r n a l  of  t h e  N at ion a l  C a n c e r  I n s t i t u t e  1 0 7  ( 2 0 1 5 ) 
most common childhood cancer (5). The introduction of antiretro-
viral therapy (ART) has decreased the incidence of AIDS, and con-
sequently epidemic KS, in resource-rich and -limited countries alike 
(6). Nevertheless, ART coverage in resource-limited countries of 
sub-Saharan Africa remains low, at approximately 37% (7). Hence, 
KS continues to be a substantial source of morbidity and mortal-
ity among HIV-infected children and adults in this region (1,8–10).
All forms of KS, along with the lymphoproliferative malig-
nancies primary effusion lymphoma and multicentric Castle-
man’s disease, are etiologically linked with Kaposi’s sarcoma–as-
sociated herpesvirus (KSHV; or human herpesvirus-8 [HHV-8]) 
(11–13). Global KSHV seroprevalence is uneven; it is low in the 
United States and Western Europe, moderate in the Mediterra-
nean, and high in sub-Saharan Africa (14–16). Concordantly, in a 
previous prospective cohort study, we observed that KSHV infec-
tion is common among Zambian children, as approximately 40% 
of children acquired KSHV by four years of age (17). KSHV DNA 
is frequently detected in saliva of infected individuals—implicat-
ing salivary exchange as the major route of transmission to chil-
dren (18,19). Indeed, we recently reported that specific child feed-
ing behaviors are associated with early childhood infection (20). 
Counseling and educating caregivers regarding KSHV transmis-
sion and feeding habit changes may therefore reduce early child-
hood infection. However, in the absence of a KSHV vaccine, coun-
seling alone cannot be anticipated to eliminate viral transmission 
and the risk of developing KS. This underscores the urgent need 
to prevent transmission of KSHV in the pediatric population, 
thereby reducing the burden of KS in both children and adults.
We previously observed that children infected with HIV had a 
five-fold higher risk of acquiring KSHV compared with HIV unin-
fected children (17). However, this cohort study was conducted be-
fore the widespread use of ART in Zambia. We hypothesized that 
HIV-induced immunosuppression predisposed children to infec-
tion by KSHV; thus prevention of CD4+ T-cell depletion and subse-
quent immune suppression by early ART should reduce KSHV inci-
dence. The Zambian government recently increased ART availability 
and, in accordance with the World Health Organization (WHO) rec-
ommendations, the current policy is to provide HIV-infected chil-
dren with ART after confirmatory diagnosis regardless of CD4+ T-
cell status (21,22). Additionally, the University Teaching Hospital 
(UTH) in Lusaka was one of the first hospitals to successfully im-
plement a routine HIV counseling and testing program for children 
(23). These programs supported investigating the relationship be-
tween immune suppression and KSHV transmission. In the pres-
ent study, we have evaluated the impact of ART on KSHV acquisi-
tion in a prospective cohort of young Zambian children.
Methods
Study Setting and Cohort
The current study is part of an ongoing observational cohort fol-
lowing children born to HIV-infected mothers to investigate the 
effect of ART on KSHV. Screening and enrollment was conducted 
between December 2009 and June 2012 at the UTH in Lusaka, 
Zambia. Local community workers recruited and informed po-
tential participants about the study aims (24). Interested moth-
ers who visited the study clinic and provided written informed 
consent to participate were given monetary compensation for 
transportation costs. Mothers were also counseled about HIV 
and KSHV infections and ways to prevent transmission. Eligibil-
ity criteria for enrollment was as follows: 1) child was less than 
12 months of age; 2) child was negative for KSHV antibodies in 
plasma and KSHV DNA in the oral cavity; 3) child HIV status was 
confirmed; and 4) mother was HIV infected. All eligible mother-
child pairs returned within a week for enrollment and were sched-
uled for follow-up every three months for up to 48 months after 
enrollment. This study was approved by the Institutional Review 
Board of the University of Nebraska and the University of Zam-
bia Biomedical Research Ethics Committee.
Data Collection and Laboratory Testing
Data and Biological Specimen Collection
Trained interviewers conducted intake interviews with each 
mother using structured questionnaires at all study visits. The 
self-reported questionnaires collected data pertaining to sociode-
mographics, medical history, laboratory results, and ART status, 
adherence, and regimen. Blood samples and oral swabs were col-
lected from all children during a free-of-charge medical examina-
tion at each study visit. Plasma and oral swabs were shipped to 
the University of Nebraska-Lincoln for KSHV antibody and DNA 
detection, respectively.
HIV Diagnosis and Blood Testing
HIV diagnosis was conducted at the UTH laboratory in Lusaka. 
Because all children were under 12 months of age, HIV testing was 
performed using DNA polymerase chain reaction (PCR) of dried 
blood spots. Confirmation of mother HIV status was performed 
using two rapid tests—Abbott RealTime HIV-1 Qualitative (Ab-
bott Laboratories, Des Plaines, IL) and Unigold Recombigen HIV-
1/2 (Trinity Biotech, Bray, Ireland)—according to manufactur-
er’s protocols. Whole blood samples of HIV-infected children were 
analyzed at the UTH clinic to determine the percentage of total 
T-cells (CD3+) that were CD4+ or CD8+ using a FacsCount Cell 
Analyzer (BD Biosciences, San Jose, CA) according to the manu-
facturer’s protocol. Blood chemistry and full blood count were also 
conducted for each child.
KSHV Detection
Plasma samples were tested for KSHV antibodies using a 
monoclonal antibody–enhanced immunofluorescence assay 
(mIFA) previously standardized in our laboratory (20). Briefly, 
plasma samples were diluted 1:40 in phosphate-buffered saline 
(PBS) and incubated on stimulated and fixed BC3 cells. Mouse 
monoclonal antihuman IgG (CRL-1786; American Type Culture 
Collection, Manassas, VA) was used as a secondary antibody and 
DyLight 488-conjugated donkey antimouse IgG (Jackson Immu-
noResearch, West Grove, PA) as the tertiary antibody. A plasma 
sample was considered KSHV positive if two readers indepen-
dently determined the sample to be positive on two separate mI-
FAs. Oral swabs collected at screening were tested for the presence 
of KSHV DNA by PCR and Southern blot analysis, as described 
previously (19,25), to verify KSHV-negative status at study entry.
Statistical Analysis
Categorical data were summarized by count and percentages 
using Chi-square test to determine statistical significance, and 
continuous variables were summarized by median and interquar-
tile range (IQR) using Wilcoxon rank-sum test for statistical sig-
nificance. Independent variables analyzed for all children, and 
HIV-infected children only, are detailed in Tables 1 and 2. Gener-
alized symptoms include any of the following: fever, sore throat, 
rash, diarrhea, vomiting, mouth sores, sneezing, or cough. Miss-
ing CD4% or CD8% data were imputed using that child’s median 
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value from other visits. Additional independent variables consid-
ered for HIV-infected children taking ART were age at ART initia-
tion (in months) and ART regimen (three nucleoside reverse tran-
scriptase inhibitors [NRTIs], two NRTIs and one non-nucleoside 
reverse transcriptase inhibitors [NNRTIs], or two NRTIs and one 
protease inhibitor [PI]). Logistic regression was used to measure 
associations between KSHV seroconversion and generalized symp-
toms or full blood count data at either the KSHV seroconversion 
visit or study censor date.
All time-to-event data were right-censored at 24 months of 
follow-up. Crude KSHV incidence rate per 100 child-months was 
calculated for all variables. Cumulative incidence curves were gen-
erated depicting the probability of KSHV infection as a function 
of age for the total cohort, HIV-uninfected vs HIVinfected chil-
dren, and HIV-uninfected vs HIV-infected children stratified by 
ART status. Univariate Cox proportional hazards modeling was 
used to assess the risk of KSHV infection for all variables, includ-
ing those associated with caregivers, for the HIV-infected chil-
dren and children taking ART. The proportional hazards assump-
tion was verified using the empirical score process. Variables that 
were statistically significant in the univariate analysis were then 
considered for multivariable Cox proportional hazards models us-
ing forward stepwise selection. Percentages of CD4+ and CD8+ T-
cells collected at each study visit were analyzed as time-updated 
data. Adjusted hazard ratios (AHRs), along with corresponding 
95% confidence intervals (CIs), are reported. All statistical tests 
were two-sided, and P values of less than or equal to .05 were con-
sidered statistically significant. Analyses were performed using 
statistical packages SAS (v9.3; SAS Institute, Cary, NC) and SPSS 
(v22; IBM, Armonk, NY).
Results
Initially, 688 children from Lusaka, Zambia, were screened for 
HIV and KSHV infections. A total of 324 eligible children were 
enrolled for follow-up, of which 287 returned for at least one fol-
low-up visit (Figure 1). Reasons for exclusion and loss to follow- 
up are detailed in Figure 1.
Table 1 summarizes the demographics of the current study co-
hort (N = 287), including HIV-uninfected (n = 196) and infected 
(n = 91) children. We detected statistically significant differences 
in maternal characteristics and child age between HIVuninfected 
and infected children (Table 1). Because the aim of our study was 
to evaluate the impact of ART on KSHV acquisition, we first inves-
tigated whether there were any differences in overall health sta-
tus between HIV-infected and uninfected children at study en-
rollment. We found that all clinical characteristics were similar 
between HIV-infected and uninfected children, with the excep-
tion of small yet statistically significant differences in hemato-
crit and monocyte levels (Table 2).
Table 1. Demographic characteristics in a longitudinal cohort of 287 children, by child HIV status, from Lusaka, Zambia, 2009–2012
 Whole cohort  Children without HIV  Children with HIV
Characteristic*  (N = 287) No. (%)  (n = 196) No. (%)  (n = 91) No. (%)  P†
Age at enrollment, mo (range)  7 (5–11)  6 (4–9)  10 (6–12)  <.001
Sex
   Female  136 (47.4)  91 (46.4)  45 (49.5)  .63
   Male  151 (52.6)  105 (53.6)  46 (50.5)
Household members, no.
   ≤3  47 (16.4)  29 (14.8)  18 (19.8)  .48
   4–5  148 (51.5)  101 (51.5)  47 (51.6)
   ≥6  92 (32.1)  66 (33.7)  26 (28.6)
Monthly household income
   ≤$30  72 (25.1)  38 (19.4)  34 (37.4)  <.001
   >$30  202 (70.4)  152 (77.5)  50 (54.9)
Unknown  13 (4.5)  6 (3.1)  7 (7.7)
Mother employment
   Unemployed  193 (67.2)  124 (63.3)  69 (75.8)  .04
   Employed  94 (32.8)  72 (36.7)  22 (24.2)
Mother education
   0–7 y  172 (59.9)  117 (59.7)  55 (60.4)  .90
   ≥8 y  115 (40.1)  79 (40.3)  36 (39.6)
Mother breastfeeding‡
   Never  14 (4.9)  11 (5.6)  3 (3.3)  .56
   Ever  273 (95.1)  185 (94.4)  88 (96.7)
Months of breastfeeding (range)  7.8 (5.2–11.8)  6.8 (5.0–10.1)  11 (6.3–14.1)  <.001
Mother ART
   Never  126 (43.9)  62 (31.6)  64 (70.3)  <.001
   Ever  161 (56.1)  134 (68.4)  27 (29.7)
Mother start ART‡§
   Before pregnancy  95 (33.1)  87 (44.4)  8 (8.8)  <.001
   During pregnancy  34 (11.8)  31 (15.8)  3 (3.3)
   After pregnancy  32 (11.1)  16 (8.2)  16 (17.6)
Months mother on ART§ (range)  17 (8–36)  24 (9–48)  7 (4–10)  <.001
* Continuous variables are represented as median (interquartile range) and categorical variables as count (percentages). ART = antiretroviral therapy;  
HIV = human immunodeficiency virus.
† Wilcoxon rank-sum test was used for continuous data and chi-square test for categorical data, except where noted. All tests were two-sided.
‡ Fisher’s exact test used. All tests were two-sided.
§ n = 161 (only mothers with history of ART).
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Table 2. Child clinical characteristics at time of enrollment in a longitudinal cohort of 287 children, by child HIV status, from Lusaka, Zambia, 
2009–2012
 Whole cohort  Children without HIV  Children with HIV
Characteristic* (N = 287) No. (%)  (n = 196) No. (%)  (n = 91) No. (%)  P†
Height, cm (range)  63 (60–69)  63 (60–69)  63.5 (60–69)  .86
Weight, kg (range)  7 (6.0–8.1)  7 (6.0–8.2)  6.9 (5.9–7.8)  .55
Developmentally appropriate‡
    No  5 (1.7)  3 (1.5)  2 (2.2)  .65
    Yes  282 (98.3)  193 (98.5)  89 (97.8)
Generalized symptoms§
    No  239 (83.3)  164 (83.7)  75 (82.4)  .79
    Yes  48 (16.7)  32 (16.3)  16 (17.6)
Alanine aminotransferase, U/L (range)  14.3 (10.4–21.1)  13.4 (9.5–19.5)  15.1 (10.7–21.6)  .14
Aspartate aminotransferase, U/L (range)  40.3 (32.7–52.4)  41.1 (32.8–52.9)  39.1 (31.6–49.5)  .55
White blood cell, x109/L (range)  10.1 (8.0–12.7)  10.1 (8–12.4)  10.1 (8.1–12.8)  .97
Hemoglobin, g/dL (range)  9.9 (9.1–10.9)  9.9 (9.1–10.6)  10.0 (9.1–11.5)  .13
Hematocrit, % (range)  30.8 (28.3–32.7)  31.2 (28.8–32.7)  30.0 (27.2–32.0)  .01
Lymphocyte, % (range)  64.2 (57.8–70.8)  65.0 (57.8–71.1)  63.1 (59.1–69.6)  .44
Monocyte, % (range)  8.4 (6.8–10.6)  8.8 (7.0–10.9)  7.9 (6.6–9.4)  .005
Child ART
    No - - - -  17 (18.7)
    Yes  - -  - -  74 (81.3)  -
CD4, % (range)  - -  - -  40.0 (31.0–57.0)  -
CD8, % (range)  - -  - -  56.0 (47.0–57.0)  -
CD4:CD8 ratio (range) - -  - -  0.74 (0.50–1.02)  -
Immunosuppression status||
    Not clinically significant  - -  - -  62 (68.1)
    Mild - -  - -  18 (19.8)
    Advanced  - -  - -  11 (12.1)  -
* Continuous variables are represented as median (interquartile range) and categorical variables as count (percentages). ART = antiretroviral therapy;  
HIV = human immunodeficiency virus.
† Wilcoxon rank-sum test was used for continuous data and chi-square test for categorical data, except where noted. All tests were two-sided.
‡ Fisher’s exact test used. All tests were two-sided.
§ Includes fever, sore throat, rash, diarrhea, vomiting, mouth sores, sneezing, or cough.
|| Based on CD4% according to age appropriate World Health Organization categories (29).
Figure 1. Flow chart 
summarizing the recruitment 
and enrollment procedures for 
the mother-child pair cohort 
in Lusaka, Zambia, 2009–2012. 
HIV = human immunodeficiency 
virus; KSHV = Kaposi’s 
sarcoma–associated herpesvirus.
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During the follow-up period, 151 (52.6%) children underwent 
KSHV seroconversion. We did not detect any associations between 
KSHV seroconversion and recent generalized symptoms when an-
alyzed individually or as a group (data not shown). Analysis of 
full blood count data revealed a statistically significant associa-
tion between KSHV seroconversion and higher total lymphocyte 
percentage (median [IQR] = 61 (53–68) vs 55 (47–62), odds ratio 
[OR] = 1.05, 95% confidence interval [CI] = 1.03 to 1.08). Higher 
lymphocyte counts suggest that acute KSHV infection occurred 
recently, despite the lack of distinguishable clinical symptoms as-
sociated with KSHV seroconversion.
The entire cohort contributed 3552 months of follow-up, with 
a median follow-up time from enrollment to seroconversion or 
censor date of 10.5 months (IQR = 4.5–22.8). Overall, we calcu-
lated an incidence rate of 4.25 KSHV infections per 100 child-
months (Table 3). We did not observe any socio-demographic, 
medical, or maternal characteristics to be statistically significantly 
associated with an increased rate of KSHV infection. We also de-
termined that the rates of KSHV infection were similar in HIV-
infected and uninfected children (Table 3 and Figure 2A). How-
ever, when HIV-infected children were stratified by ART status 
prior to KSHV seroconversion or censor date, ART-naive children 
had a statistically significantly increased rate of KSHV acquisi-
tion compared with HIV-uninfected children (incidence rate ratio 
[IRR] = 5.97, 95% CI = 3.13 to 11.41). In contrast, the HIVinfected 
children taking ART acquired KSHV at a rate indistinguishable 
from HIV-uninfected controls (IRR = 0.99, 95% CI = 0.68 to 1.43) 
(Table 3 and Figure 2B). The cumulative probability of KSHV in-
fection was also statistically significantly higher in ART-naive 
HIV-infected children when age of the child was analyzed as the 
time-dependent variable (P < .001) (Supplementary Figure 1).
Among HIV-infected children, baseline demographic, mater-
nal, and clinical characteristics were similar between ART-treated 
and ART-naive children, with the exception of age and age-related 
Table 3. Crude incidence rate of KSHV per 100 child-months since time of enrollment in a longitudinal cohort of 287 children from Lusaka, 
Zambia, 2009–2012*
KSHV-positive KSHV-free Incidence rate
Characteristic  No. of children children  % child-months per 100 child-months  IRR (95% CI)
Total  287  151  52.6  3552  4.25  - -
Mother ART
Never  126  71  56.3  1431  4.96  Ref.
Ever  161  80  49.7  2120  3.77  0.76 (0.55 to 1.05)
Child HIV status
Negative  196  100  51.0  2512  3.98  Ref.
Positive  91  51  56.0  1040  4.90  1.23 (0.88 to 1.73)
Child HIV/ART status
HIV(-)  196  100  51.0  2512  3.98  Ref.
HIV(+)/ART(+)  74  39  52.7  989.6  3.94  0.99 (0.68 to 1.43)
HIV(+)/ART(-)  17  12  70.6  50.47  23.78  5.97 (3.13 to 11.41)
* ART = antiretroviral therapy; CI = confidence interval; HIV = human immunodeficiency virus; IRR = incidence rate ratio; KSHV = Kaposi’s sar-
coma–associated herpesvirus.
Figure 2. Kaplan-Meier 
plots estimating the 
probability of remaining 
Kaposi’s sarcoma–associated 
herpesvirus–free since 
enrollment in a longitudinal 
cohort of 287 children from 
Lusaka, Zambia, 2009–2012. 
A) Probabilities stratified 
by child HIV status. B) 
Probabilities stratified by 
child HIV and antiretroviral 
status. Vertical lines 
indicate censoring. Log-rank 
test was used to calculate 
statistical significance. All 
tests were two-sided. ART 
= antiretroviral therapy; HIV 
= human immunodeficiency 
virus; KSHV = Kaposi’s 
sarcoma–associated 
herpesvirus.
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variables (Supplementary Table 1, available online). In multivari-
able Cox proportional hazard analysis among HIV-infected chil-
dren, we found that the absence of ART statistically significantly 
increased the risk of KSHV acquisition (AHR = 5.04, 95% CI = 2.36 
to 10.80, P < .001). Time-updated CD4+ T-cell percentage was also 
statistically significantly associated with risk of KSHV acquisition 
(AHR = 0.82, 95% CI = 0.74 to 0.92, P < .001), such that each 5% 
increase of CD4+ T-cells represented an 18% decrease in risk of 
acquiring KSHV (Table 4). In order to investigate for possible as-
sociations of KSHV infection with the age at which ART was ini-
tiated or the ART regimen received, we analyzed data from HIV-
infected children actively taking ART. The distribution of specific 
ART regimens among the HIV-infected children are presented in 
Supplementary Figure 2 (available online), and we found no dif-
ferences in KSHV acquisition by ART regimen. Similar to all chil-
dren infected with HIV, however, we found that higher CD4% in 
children taking ART was associated with a decreased risk of KSHV 
infection (AHR = 0.83, 95% CI = 0.73 to 0.93, P = .002). The ob-
served risks of KSHV infection were similar whether or not age 
and sex,were included in the models (Table 4).
Discussion
This is the first study to investigate the effect of ART on KSHV 
incidence in HIV-infected children. Several cross-sectional stud-
ies conducted in sub-Saharan Africa have demonstrated higher 
KSHV seroprevalence among HIV-infected children compared 
with HIV-uninfected children (26–28). Our previous longitudi-
nal cohort study in Zambia further established that HIV-infected 
children were five-fold more likely to acquire KSHV (17). However, 
these studies were conducted prior to the introduction of ART 
in sub-Saharan Africa. In the present study, we observed similar 
rates of KSHV acquisition between HIV-infected and uninfected 
children—likely because of the implementation of effective ART 
among HIV-infected children in Zambia. Consistent with this con-
cept and our previous findings, we also observed that HIVinfected 
ART-naive children were five-fold more likely to acquire KSHV 
compared with HIV-infected children taking ART.
ART success is routinely assessed by CD4+ T-cell levels. Since 
CD4 count varies in young children, because of normal infant 
lymphocytosis or factors such as malnutrition and infections, we 
used CD4 percentage as a more reliable measure for immune sta-
tus (29). Although very few HIV-infected children in our cohort 
were classified with advanced immunosuppression by WHO CD4% 
categories, we did detect statistically significantly lower risk of 
KSHV infection among children with higher CD4+ T-cell percent-
ages. This data supports the hypothesis that the risk of acquiring 
KSHV among HIV-infected children is related to CD4+ T-cell de-
pletion and subsequent HIV-induced immune dysfunction. The 
specific immune dysfunction that would confer susceptibility to 
KSHV infection is unknown. Activated B-cells support KSHV in-
fection and replication, whereas resting B-cells do not (30); there-
fore, B-cell hyperactivity, functional reduction of cytotoxic T-lym-
phocytes, and the pro-inflammatory state triggered by HIV may 
create an environment conducive for KSHV infection. Initiation 
of ART reduced immune activation in a different cohort of HIV-in-
fected Zambian children (31). Furthermore, early ART statistically 
significantly reduced allcause mortality and HIV disease progres-
sion in the Children with HIV Early Antiretroviral (CHER) trial 
(32). Coupled with the present data, it is likely that ART initiation 
within weeks of HIV infection, as was the case in our cohort, may 
protect and maintain normal immune functions, thereby reduc-
ing KSHV incidence and ultimately the burden of KS.
Alternatively, ART might be directly inhibiting KSHV acquisi-
tion. A recent study revealed that nelfinavir inhibited KSHV repli-
cation in vitro, but all other antiretrovirals tested—including mul-
tiple NRTIs, NNRTIs, and PIs—had no effect (33). Nelfinavir was 
not prescribed to any children in the present cohort; nevertheless, 
ART was still associated with lower risk of KSHV acquisition. Con-
sequently, whether any ART components can directly prevent new 
KSHV infection or establishment of latency is unclear. Longitudi-
nal follow- up of children after recent KSHV acquisition will allow 
us to delineate the impact of ART on KSHV latency and replica-
tion during the early stages of infection in HIV-infected children.
Our cohort study has several strengths, which include pro-
spective design, regular and frequent follow-up visits, and a large 
number of HIV-infected children with access to ART. However, 
there are some limitations. Many children were not enrolled in 
the study because of evidence of prior KSHV seroconversion; 
therefore, the incidence measures described in this report are 
likely to underrepresent the true incidence among HIV-exposed 
Table 4. Multivariable Cox regression models for risk of KSHV acquisition since time of enrollment among 91 HIV-infected children in a longi-
tudinal cohort of 287 children from Lusaka, Zambia, 2009–2012
                                                                                                  Model 1*  Model 2*
Characteristic HR (95% CI)  P†  HR (95% CI)  P†
HIV+ children
Absence of ART  5.04 (2.36 to 10.80) <.001  4.34 (1.94 to 9.70)  <.001
   CD4% (5% intervals)  0.82 (0.74 to 0.92)  <.001  0.83 (0.74 to 0.92)  <.001
   Age at enrollment, mo  - -  - 0.96 (0.88 to 1.05)  .37
   Male sex  - -  - 1.33 (0.76 to 2.34)  .31
ART+ children
   CD4% (5% intervals)  0.83 (0.73 to 0.93)  .002 0.85 (0.75 to 0.96)  .008
   Age at enrollment, mo  - -  - 0.98 (0.88 to 1.08)  .63
   Male sex  - -  - 1.72 (0.88 to 3.32)  .11
* Model 1 was adjusted for antiretroviral therapy (ART) status and CD4% among HIV+ children and CD4%  alone among ART+ children. Model 
2 was also adjusted for age and sex. ART = antiretroviral therapy; CI = confidence interval; HIV = human immunodeficiency virus; HR = haz-
ard ratio; KSHV = Kaposi’s sarcoma–associated herpesvirus.
† Chi-square test was used to calculate P values. All tests were two-sided.
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children. Additionally, our mIFA is unable to distinguish be-
tween a primary or secondary seroconversion, as it detects IgG 
antibodies but not IgM. However, we have several other rea-
sons to be confident that the seroconversion event represents 
primary KSHV acquisition: We enrolled very young children, 
KSHV was not detected in saliva of children at enrollment, and 
we observed an association between KSHV seroconversion and 
higher lymphocyte percentage. A final limitation was the low 
number of ART-naive children in our cohort. This was expected, 
because ART was offered to all HIV-infected children as part of 
the study—consistent with strong ethical practices. Neverthe-
less, there were still a number of caregivers who decided not to 
start ART for their children, regardless of being counseled about 
the importance of early treatment. Although many factors re-
lated to the mother were not associated with KSHV acquisition, 
it is possible that these caregivers may have performed behav-
iors that we did not assess, such as specific feeding habits, fur-
ther increasing risk of KSHV transmission. Despite these lim-
itations, we still observed a large and statistically significant 
increase in risk of KSHV acquisition among ART-naive children. 
Our findings are directly applicable to HIVinfected children in 
Zambia, a resource-limited country with high KSHV/HIV prev-
alence and early childhood acquisition. Our findings may also 
be applicable to other countries in the region, but not in other 
settings where KSHV/HIV prevalence or ART coverage differs 
substantially. Treatment with ART is not directly applicable to 
HIV-uninfected children at risk for KSHV infection, although 
reducing the overall number of KSHV infections and transmis-
sion sources may in turn reduce the risk of KSHV transmission 
to HIV-uninfected children.
We did not detect associations between KSHV infection and 
the age of the child at ART initiation or type of ART regimen in 
Cox proportional hazard analysis. These data should not be in-
terpreted that ART-related variables are unimportant for reduc-
ing KSHV incidence, but rather that our cohort was not designed 
to investigate these variables. Children in our cohort were re-
cruited and followed at very young ages, therefore restricting 
the ART initiation age range that could be analyzed. Addition-
ally, although three major ART regimens were represented in 
our cohort, over 80% of the children were taking a two-NRTI-
and-one-NNRTI regimen. Numerous studies have demonstrated 
that ART can reduce progression of KS (34), and one suggests PI-
based regimens may be more effective than others (35). There-
fore, our observation that ART is also associated with a lower 
risk of acquiring KSHV warrants further research into whether 
particular ART regimens are more effective at preventing new 
KSHV infections.
Because a vaccine against KSHV is not available and efforts 
to develop one are limited (36), it is paramount to develop alter-
native strategies to prevent KSHV acquisition during early child-
hood. Our data suggest that ART and prevention of immune sup-
pression play an important role in reducing the incidence and 
risk of KSHV acquisition among HIV-infected children in an area 
where both viruses are highly endemic. The WHO is currently ad-
vocating ART programs for HIV-infected pregnant women and 
their children to prevent new HIV infections and increase treat-
ment retention (37). Our data highlight the importance of these 
efforts and additional programs to provide ART to children as 
soon as HIV infection is diagnosed, not only to reduce HIV-asso-
ciated morbidity but also help prevent KSHV infection and reduce 
the burden of KS among HIV-infected children.
Acknowledgments — This work was supported by the US National Insti-
tutes of Health (NIH; grant numbers R01 CA75903, P30 GM103509, T32 
AI060547 to CW) and the US Fogarty International Center (grant num-
ber D43 TW01492 to CW). LNO was supported in part by the NIH under 
a Ruth L. Kirschstein National Research Service Award from the National 
Institute of Allergy and Infectious Diseases and by a Maude Hammond 
Fling Fellowship from the University of Nebraska-Lincoln. CG was sup-
ported as a Fogarty Fellow.
The funders had no role in the design of the study, the collection, 
analysis, or interpretation of the data, the writing of the manuscript, or 
the decision to submit the manuscript for publication. We declare that 
we have no conflicts of interest. We thank all children and caregivers for 
their participation in the study, as well as community health workers and 
laboratory staff at UTH in Lusaka for their contributions to recruitment, 
data management, and sample processing.
VM, CK, JW, CM, and CW conceived and designed the study. LNO, 
VM, and CG collected data, LNO and VM analyzed data and performed 
statistical analyses, and LNO wrote the first draft of the report. All au-
thors interpreted the data, revised the drafts, and approved the final 
version.
References
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence 
and mortality worldwide: Sources, methods and major pat-
terns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 
2015;136(5):E359–E386.
2. Oettle AG. Geographical and racial differences in the fre-
quency of Kaposi’s sarcoma as evidence of environmental or 
genetic causes. Acta – Unio Internationalis Contra Cancrum. 
1962;18:330–363.
3. Cook-Mozaffari P, Newton R, Beral V, et al. The geographical dis-
tribution of Kaposi’s sarcoma and of lymphomas in Africa be-
fore the AIDS epidemic. Br J Cancer. 1998;78(11):1521–1528.
4. Parkin DM, Sitas F, Chirenje M, et al. Part I: Cancer in Indige-
nous Africans— burden, distribution, and trends. Lancet Oncol. 
2008;9(7):683–692.
5. Chintu C, Athale UH, Patil PS. Childhood cancers in Zam-
bia before and after the HIV epidemic. Arch Dis Child. 
1995;73(2):100–105.
6. Bohlius J, Valeri F, Maskew M, et al. Kaposi’s Sarcoma in HIV-in-
fected patients in South Africa: Multicohort study in the anti-
retroviral therapy era. Int J Cancer. 2014;135(11):2644–2652.
7. UNAIDS. HIV Fact Sheet. http://www.unaids.org/sites/default/
files/media_asset/20140716_FactSheet_en.pdf. Accessed No-
vember 28, 2014.
8. Tukei VJ, Kekitiinwa A, Beasley RP. Prevalence and out-
come of HIV-associated malignancies among children. AIDS. 
2011;25(14):1789–1793.
9. Slone JS, Chunda-Liyoka C, Perez M, et al. Pediatric Malignan-
cies, Treatment Outcomes and Abandonment of Pediatric Can-
cer Treatment in Zambia. PLoSONE. 2014;9(2):e89102.
10. Davidson A, Wainwright RD, Stones DK, et al. Malignancies 
in South African children with HIV. J Pediatr Hematol Oncol. 
2014;36(2):111–117.
11. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes-
viruslike DNA sequences in AIDS-associated Kaposi’s sarcoma. 
Science. 1994;266(5192):1865–1869.
12. Cesarman E, Chang Y, Moore PS, et al. Kaposi’s Sarcoma–
Associated Herpesvirus- Like DNA Sequences in AIDS-Re-
lated Body-Cavity–Based Lymphomas. New Engl J Med. 
1995;332(18):1186–1191.
8 L . N .  O l p  e t  a l  i n  J C N I  J o u r n a l  of  t h e  N at ion a l  C a n c e r  I n s t i t u t e  1 0 7  ( 2 0 1 5 ) 
13. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-as-
sociated herpesvirus- like DNA sequences in multicentric Cas-
tleman’s disease. Blood. 1995;86(4):1276–1280.
14. Dedicoat M, Newton R. Review of the distribution of Kaposi’s 
sarcoma-associated herpesvirus (KSHV) in Africa in relation to 
the incidence of Kaposi’s sarcoma. Br J Cancer. 2003;88(1):1–3.
15. Gao S-J, Kingsley L, Li M, et al. KSHV antibodies among Amer-
icans, Italians and Ugandans with and without Kaposi’s sar-
coma. Nat Med. 1996;2(8):925–928.
16. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi’s 
sarcoma associated herpesvirus infection measured by antibod-
ies to recombinant capsid protein and latent immunofluores-
cence antigen. Lancet. 1996;348(9035):1133–1138.
17. Minhas V, Crabtree KL, Chao A, et al. Early Childhood Infection 
by Human Herpesvirus 8 in Zambia and the Role of Human Im-
munodeficiency Virus Type 1 Coinfection in a Highly Endemic 
Area. Am J Epidemiol. 2008;168(3):311–320.
18. Mbulaiteye SM, Pfeiffer RM, Engels EA, et al. Detection of Ka-
posi Sarcoma— Associated Herpesvirus DNA in Saliva and 
Buffy-Coat Samples from Children with Sickle Cell Disease in 
Uganda. J Infect Dis. 2004;190(8):1382–1386.
19. Brayfield BP, Kankasa C, West JT, et al. Distribution of Kaposi 
Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 in Ma-
ternal Saliva and Breast Milk in Zambia: Implications for Trans-
mission. J Infect Dis. 2004;189(12):2260–2270.
20. Crabtree KL, Wojcicki JM, Minhas V, et al. Risk Factors for Early 
Childhood Infection of Human Herpesvirus-8 in Zambian Chil-
dren: The Role of Early Childhood Feeding Practices. Cancer Epi-
demiol Biomarkers Prev. 2014;23(2):300– 308.
21. Republic of Zambia Ministry of Health. Guidlines for Antiretro-
viral Therapy for HIV in Infants and Children in Zambia. http://
www.emtct-iatt.org/wpcontent/uploads/2014/05/Zambia-pe-
diatric-guidelines-2010.pdf. Accessed March 27, 2015.
22. WHO. Report of the WHO Technical Reference Group, Paediat-
ric HIV/ART Care Guideline Group Meeting. http://www.who.
int/hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_
mreport_2008.pdf. Accessed March 27, 2015.
23. Kankasa C, Carter RJ, Briggs N, et al. Routine offering of HIV 
testing to hospitalized pediatric patients at university teaching 
hospital, Lusaka, Zambia: acceptability and feasibility. J Acquir 
Immune Defic Syndr. 2009;51(2):202–208.
24. Minhas V, Crabtree KL, Chao A, et al. The Zambia Children’s KS-
HHV8 Study:Rationale, Study Design, and Study Methods. Am 
J Epidemiol. 2011;173(9):1085–1092.
25. Olp LN, Shea DM, White MK, et al. Early childhood infec-
tion of Kaposi’s sarcoma- associated herpesvirus in Zam-
bian households: A molecular analysis. Int J Cancer. 
2013;132(5):1182–1190.
26. Wakeham K, Webb EL, Sebina I, et al. Risk Factors for Se-
ropositivity to Kaposi Sarcoma-Associated Herpesvirus 
Among Children in Uganda. J Acquir Immune Defic Syndr. 
2013;63(2):228–233.
27. Minhas V, Brayfield BP, Crabtree KL, et al. Primary gamma-
herpesviral infection in Zambian children. BMC Infect Dis. 
2010;10(1):115.
28. Dedicoat M, Newton R, Alkharsah KR, et al. Mother-to-Child 
Transmission of Human Herpesvirus-8 in South Africa. J Infect 
Dis. 2004;190(6):1068–1075.
29. WHO. Interim WHO Clinical Staging of HIV/AIDS and HIV/
AIDS Case Definitions for Surveillence. http://www.who.int/
hiv/pub/guidelines/clinicalstaging.pdf. Accessed August 28, 
2014.
30. Rappocciolo G, Hensler HR, Jais M, et al. Human Herpesvirus 8 
Infects and Replicates in Primary Cultures of Activated B Lym-
phocytes through DCSIGN. J Virol. 2008;82(10):4793–4806.
31. Rainwater-Lovett K, Nkamba H, Mubiana-Mbewe M, et al. 
Changes in Cellular Immune Activation and Memory T-Cell 
Subsets in HIV-Infected Zambian Children Receiving HAART. J 
Acquir Immune Defic Syndr. 2014;67(5):455–462.
32. Cotton MF, Violari A, Otwombe K, et al. Early time-limited an-
tiretroviral therapy versus deferred therapy in South Afri-
can infants infected with HIV: results from the children with 
HIV early antiretroviral (CHER) randomised trial. Lancet. 
2013;382(9904):1555–1563.
33. Gantt S, Carlsson J, Ikoma M, et al. The HIV Protease Inhib-
itor Nelfinavir Inhibits Kaposi’s Sarcoma-Associated Her-
pesvirus Replication In Vitro. Antimicrob Agents Chemother. 
2011;55(6):2696–2703.
34. Krown SE. Highly Active Antiretroviral Therapy in AIDS-Associ-
ated Kaposi’s Sarcoma: Implications for the Design of Therapeu-
tic Trials in Patients With Advanced, Symptomatic Kaposi’s Sar-
coma. J Clin Oncol. 2004;22(3):399–402.
35. Leitch H, Trudeau M, Routy JP. Effect of Protease Inhibitor-
Based Highly Active Antiretroviral Therapy on Survival in HIV-
Associated Advanced Kaposi’s Sarcoma Patients Treated with 
Chemotherapy. HIV Clin Trials. 2003;4(2):107–114.
36. Wu TT, Qian J, Ang J, et al. Vaccine prospect of Kaposi sarcoma-
associated herpesvirus. Curr Opin Virol. 2012;2(4):482–488.
37. WHO. Use of Antiretroviral Drugs for Treating Pregnant 
Women and Preventing HIV Infection in Infants. http://whqlib-
doc.who.int/hq/2012/WHO_HIV_2012.6_eng.pdf?ua=1. Ac-
cessed August 28, 2014.
 Supplementary Figure 1 
 
Supplementary Figure 1. Cumulative incidence analysis estimating the probability of KSHV infection 
since birth in a longitudinal cohort of 287 children from Lusaka, Zambia, 2009 – 2012. (A) Total cohort 
incidence. (B) Incidence stratified by child HIV status. (C) Incidence stratified by child HIV and ART status. 
Vertical lines indicate censoring.  
Supplementary Figure 2 
 
Supplementary Figure 2. Distribution of ART regimen of 74 HIV-infected children in a longitudinal cohort 
of 287 children from Lusaka, Zambia, 2009 – 2012. ABC = abacavir; AZT = zidovudine; D4T = stavudine; 
NVP = nevirapine; 3TC = lamivudine. 
 
  
Supplementary Table 1: Demographic and child clinical characteristics of 91 HIV-infected 
children, by child ART status, in a longitudinal cohort of 287 children from Lusaka, Zambia, 
2009 – 2012. 
Characteristic* Children taking ART   Children not taking ART p-value# 
(n = 74) (n = 17) 
Age at Enrollment, Mean (range) 
months  
11 (8 - 12)   6 (4 - 8) < 0.001 
Gender             
  Female 38 51.4%   7 41.2% 0.45 
  Male 36 48.6%   10 58.8%   
Household Members†              
  < 3 14 18.9%   4 23.5% 0.83 
  4 - 5 38 51.4%   9 53.0%   
  > 6 22 29.7%   4 23.5%   
Monthly Household Income†              
  < $30 24 32.4%   10 58.8% 0.06 
  > $30 45 60.8%   5 29.4%   
  Unknown 5 6.8%   2 11.8%   
Mother Employment†              
  Unemployed 56 75.7%   13 76.5% 1.00 
  Employed 18 24.3%   4 23.5%   
Mother Education             
  0 - 7 years 47 63.5%   8 47.1% 0.21 
  > 8 years 27 36.5%   9 52.9%   
Mother Breastfeeding†              
  Never 3 4.0%   0 0.0% 1.00 
  Ever 71 96.0%   17 100.0%   
Months of Breastfeeding 12 (7 - 16)   6 (6 - 8) < 0.001 
Mother ART†             
  Never 49 66.2%   15 88.2% 0.09 
  Ever 25 33.8%   2 11.8%   
Mother start ART†‡             
  Before pregnancy 7 28.0%   1 50.0% 0.08 
  During pregnancy 2 8.0%   1 50.0%   
  After pregnancy 16 64.0%   0 0.0%   
Months Mother on ART‡ 7 (4 - 10)   -§ - - 
Height (cm) 67 (61 - 70)   63 (57 - 67) 0.04 
Weight (kg) 7.3 (6.1 - 8.5) 6.5 (5.8 - 6.9) 0.03 
Developmentally Appropriate†             
  No 2 2.7%   1 5.9% 0.47 
  Yes 72 97.3%   16 94.1%   
Generalized Symptomsǁ             
  No 54 73.0%   10 58.8% 0.25 
  Yes 20 27.0%   7 41.2%   
Alanine Aminotransferase (U/L) 14.5 (10.1 - 22.8) 12.4 (9.1 - 21.9) 0.37 
Aspartate Aminotransferase (U/L) 39.7 (31.2 - 59.0) 39.2 (29.4 - 56.0) 0.59 
White Blood Cell (x109/L) 10.8 (8.3 - 15.3)   8.9 (7.7 - 16.1) 0.44 
Hemoglobin (g/dL) 9.5 (8.6 - 11.0)   9.9 (9.3 - 11.2) 0.51 
Hematocrit (%) 29.1 (26.9 - 31.0) 29.5 (25.5 - 31.0) 0.94 
Lymphocyte (%) 63.1 (56.1 - 68.8) 64.3 (60.5 - 71.1) 0.24 
Monocyte (%) 8.7 (6.6 - 9.9)   8.1 (7.5 - 9.8) 0.79 
CD4 (%) 41.5 (32.0 - 57.0) 37 (27.0 - 46.0) 0.34 
CD8 (%) 54.5 (46.0 - 57.0) 57 (55.0 - 60.0) 0.07 
CD4:CD8 Ratio 0.78 (0.54 - 1.19) 0.64 (0.47 - 0.82) 0.21 
Immunosuppression Status¶             
  Not Significant 52 70.3%   10 58.8% 0.21 
  Mild 12 16.2%   6 35.3%   
  Advanced 10 13.5%   1 5.9%   
* Continuous variables are represented as median (IQR) and categorical variables as  
  count (percentages).  
† Fischer's exact test used. All tests were two-sided.  
‡ n = 27 (Only mothers with history of ART). 
§ ART duration only available from one mother. 
ǁ Includes fever, sore throat, rash, diarrhea, vomiting, mouth sores, sneezing, or cough. 
¶ Based on CD4% according to age appropriate WHO categories [29]. 
#Wilcoxon rank-sum test was used for continuous data and chi-square test for categorical data, except where noted. All tests 
were two-sided 
 
 
